Zobrazeno 1 - 10
of 164
pro vyhledávání: '"Xiang Yuan Wu"'
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/1d2293a7401d491eb46c815a459dc167
Autor:
Xing Li, Jie Chen, Yong-Jian Chen, Yi-Dan Qiao, Li-Yun Zhao, Nan Jiang, Xiang-Yuan Wu, Yan-Fang Xing
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-12 (2021)
Li et al. show that dexamethasone and lactoferrin induced polymorphonuclear myeloid-derived suppressor cells relieve inflammatory conditions in mouse models with minimal effect on tumour growth. This work demonstrates promise for combating inflammato
Externí odkaz:
https://doaj.org/article/a5f0da4bd4164d039b55198c4e4188a9
Autor:
Zhan-Hong Chen, Jing-Jing Qi, Qi-Nian Wu, Jia-Huan Lu, Ze-Xian Liu, Yun Wang, Pei-Shan Hu, Ting Li, Jin-Fei Lin, Xiang-Yuan Wu, Lei Miao, Zhao-Lei Zeng, Dan Xie, Huai-Qiang Ju, Rui-Hua Xu, Feng Wang
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-18 (2019)
Abstract Background Deregulation of protein translation control is a hallmark of cancers. Eukaryotic initiation factor 4A2 (EIF4A2) is required for mRNA binding to ribosome and plays an important role in translation initiation. However, little is kno
Externí odkaz:
https://doaj.org/article/4898116ca4344a52a40623baf9ce1d26
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: Blood-based tumor mutational burden (bTMB) was recently found to be suboptimal in predicting overall survival (OS) benefits of atezolizumab over docetaxel among patients with advanced non-small cell lung cancer (NSCLC). The maximum somati
Externí odkaz:
https://doaj.org/article/10a4cd5a57f040d79516e31d540b2b71
Autor:
Rui-Hua Xu, Yu-Hong Li, Feng-Hua Wang, Dong-Sheng Zhang, Hui-Yan Luo, Shuang-Zhen Chen, Si-Mei Shi, Ying Guo, Hong Qiu, Zhi-Qiang Wang, Zong-Jiong Mai, Ying Jin, Xiang-Yuan Wu, Zeng-Qing Guo, Qing-Feng Zou, Ying Yuan, Jie-Er Ying, Fu-Xiang Zhou, Zhi-Xiang Zhuang, Yi-Chen Yao, Zhi-Gang Ma, Xiao-Hua Hu, Wei Wang, Yan Zhang, Wei-Jia Fang, Xiang-Lin Yuan, Yan-Qiao Zhang, Jian Xiao, Ming-Ming He, Feng Wang
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b06772fe70faec5ac401fdfce8e7dbf
https://doi.org/10.1158/1078-0432.22488381.v1
https://doi.org/10.1158/1078-0432.22488381.v1
Autor:
Rui-Hua Xu, Yu-Hong Li, Feng-Hua Wang, Dong-Sheng Zhang, Hui-Yan Luo, Shuang-Zhen Chen, Si-Mei Shi, Ying Guo, Hong Qiu, Zhi-Qiang Wang, Zong-Jiong Mai, Ying Jin, Xiang-Yuan Wu, Zeng-Qing Guo, Qing-Feng Zou, Ying Yuan, Jie-Er Ying, Fu-Xiang Zhou, Zhi-Xiang Zhuang, Yi-Chen Yao, Zhi-Gang Ma, Xiao-Hua Hu, Wei Wang, Yan Zhang, Wei-Jia Fang, Xiang-Lin Yuan, Yan-Qiao Zhang, Jian Xiao, Ming-Ming He, Feng Wang
Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ddb2013da603b76379f8a09fb0d76e8
https://doi.org/10.1158/1078-0432.22488387.v1
https://doi.org/10.1158/1078-0432.22488387.v1
Publikováno v:
World Journal of Clinical Cases
BACKGROUND Targeted therapy based on pathway analysis of hepatitis B-related hepatocellular carcinoma (HCC) may be a promising remedy. CASE SUMMARY The present case involved an advanced hepatocellular carcinoma (HCC) patient who did not receive local
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ffea3c15ee9111bb5ec8ffe1523fa24
http://europepmc.org/articles/PMC8409191
http://europepmc.org/articles/PMC8409191
Autor:
Kai Yu, Qi Zhao, Qi Meng, Rui-Hua Xu, Yang Li, Long Bai, Zexian Liu, Ting Li, Huai-Qiang Ju, Junzhong Lin, Min Wang, Dan-Yun Ruan, De Shen Wang, Xiang-Yuan Wu, Li-Zhi Luo, Ying-Nan Wang, Jin-Fei Lin
Publikováno v:
Oncogene
Fat mass and obesity-associated protein (FTO), an N6-methyladenosine (m6A) demethylase, participates in tumor progression and metastasis in many malignancies, but its role in colorectal cancer (CRC) is still unclear. Here, we found that FTO protein l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6237619eecaac05300f161964cdf25e0
http://europepmc.org/articles/PMC8376648
http://europepmc.org/articles/PMC8376648
Autor:
Qi Zhang, Dong-Hao Wu, Xiang-Yuan Wu, Ying-fen Hong, Hui-qiang Huang, Zhan-Hong Chen, Chang-Chang Jia, Tian-Tian Wang, Yang Li
Publikováno v:
Biochemical and Biophysical Research Communications. 558:14-21
Sorafenib remains the standard first-line treatment for advanced hepatocellular carcinoma (HCC), although other clinical trials are currently underway for treatments that show better curative effects. However, some patients are not sensitive to soraf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b06422124bd937a6545abfeaa0a42e81
https://doi.org/10.1016/j.bbrc.2021.04.047
https://doi.org/10.1016/j.bbrc.2021.04.047
Autor:
Yi-Dan Qiao, Jian-Liang Xu, Xiang-Yuan Wu, Qing-Jian Ye, Xing Li, Nan Jiang, Hui Zhang, Jie Chen
Publikováno v:
Cancer Letters. 499:85-98
CD45+CD71+ erythroid cells generated through splenic extramedullary erythropoiesis have recently been found to suppress anti-infection and tumor immunity in neonates and adults with malignances. However, their role in tumor microenvironment has not b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c6301d29da13d78405fb0e81c2eae18
https://doi.org/10.1016/j.canlet.2020.12.003
https://doi.org/10.1016/j.canlet.2020.12.003